2.545  -0.12 (-4.5%)		12-15 15:59
Open: 2.71 High: 2.8199 Volume: 1,718,015		Pre. Close: 2.665 Low: 2.535 Market Cap: 189(M)

Short term
Mid term
Targets	6-month :	3.37	1-year :	3.94
Resists	First :	2.89	Second :	3.37
Pivot price	2.37
Supports	First :	2.31	Second :	1.96
MAs	MA(5) :	2.59	MA(20) :	2.32
	MA(100) :	3.18	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	75.7	D(3) :	84.7
RSI	RSI(14): 52.5
52-week	High :	5.38	Low :	1.6

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CATX ] has closed below upper band by 26.7%. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	2.82 - 2.84	2.84 - 2.85
Low:	2.5 - 2.52	2.52 - 2.53
Close:	2.52 - 2.55	2.55 - 2.57

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Sat, 06 Dec 2025
Affinity Asset Advisors LLC Decreases Holdings in Perspective Therapeutics, Inc. $CATX - MarketBeat

Thu, 04 Dec 2025
Perspective Therapeutics Announces Acceptance of VMT-α-NET - GlobeNewswire

Mon, 01 Dec 2025
Perspective Therapeutics Updates Corporate Presentation on Advancements - TipRanks

Thu, 20 Nov 2025
Perspective (CATX) to meet investors at Piper Sandler and Evercore healthcare events - Stock Titan

Fri, 14 Nov 2025
Williamson buys Perspective Therapeutics (CATX) shares worth $19,945 - Investing.com

Fri, 31 Oct 2025
Perspective Therapeutics to Participate in Upcoming November Conferences - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.